Published in Blood Cancer J on September 07, 2012
A new method for high-resolution imaging of Ku foci to decipher mechanisms of DNA double-strand break repair. J Cell Biol (2013) 1.29
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers (Basel) (2017) 0.78
On the origin of cancer cells. Science (1956) 49.55
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83
The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell (1993) 7.17
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
IgH class switching and translocations use a robust non-classical end-joining pathway. Nature (2007) 6.05
Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science (1994) 4.99
Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer (2005) 4.66
Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci U S A (1997) 4.13
Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. Cell (1996) 4.11
DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature (2000) 4.10
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature (2003) 3.77
The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc Natl Acad Sci U S A (2000) 3.21
Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol (1999) 2.98
Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol Cell Biol (2000) 2.93
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71
Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci U S A (2006) 2.71
Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest (1981) 2.68
Binding of Ku protein to DNA. Measurement of affinity for ends and demonstration of binding to nicks. J Biol Chem (1993) 2.66
Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood (2006) 2.02
Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol (2005) 1.82
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood (2006) 1.50
From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med (2001) 1.45
Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest (2003) 1.36
Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood (2000) 1.27
Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res (1996) 1.20
Chromosomal location and expression of the genes coding for Ku p70 and p80 in human cell lines and normal tissues. Cytogenet Cell Genet (1994) 1.17
Inhibition of apoptosis by the actin-regulatory protein gelsolin. EMBO J (1997) 1.16
Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol (2004) 1.15
Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet (2002) 1.11
Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res (2007) 1.07
Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study. Proteomics (2006) 1.04
Phospholipase A(2) of peroxiredoxin 6 has a critical role in tumor necrosis factor-induced apoptosis. Cell Death Differ (2011) 1.00
Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. Blood Rev (2004) 1.00
Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood (2002) 0.98
A mammalian monothiol glutaredoxin, Grx3, is critical for cell cycle progression during embryogenesis. FEBS J (2011) 0.97
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol (2003) 0.95
Annexin A6-Linking Ca(2+) signaling with cholesterol transport. Biochim Biophys Acta (2010) 0.94
DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood (1998) 0.94
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood (2011) 0.87
Genomic profiles in B cell lymphoma. Int J Hematol (2010) 0.84
Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol (2010) 0.84
Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. Blood (2005) 0.81
Expression of DNA repair gene Ku80 in lymphoid neoplasm. Eur J Haematol (2005) 0.81
Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. Br J Haematol (2010) 0.79
Expression of DNA-PKcs and Ku86, but not Ku70, differs between lymphoid malignancies. Exp Mol Pathol (2004) 0.78
Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor? Clin Lymphoma (2005) 0.77
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 4.69
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature (1991) 3.87
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant (2010) 3.46
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci U S A (1997) 2.10
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol (1999) 1.91
Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology (2000) 1.86
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol (1998) 1.84
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect (1998) 1.82
Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. J Immunol (1998) 1.69
Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med (1995) 1.67
Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet (1999) 1.60
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol (1997) 1.59
Allelic repertoire of the human MHC class I MICA gene. Immunogenetics (1996) 1.57
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia (2008) 1.55
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Reversible inhibitory effects and absence of toxicity of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture. Exp Hematol (1992) 1.49
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol (1995) 1.48
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol (2001) 1.47
Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol (2000) 1.43
Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci U S A (1992) 1.43
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
[Long-term effects of splenectomy for immune thrombopenic purpura related to human immunodeficiency virus. A retrospective study from 2 groups, with and without splenectomy]. Presse Med (1992) 1.41
Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol (2003) 1.40
Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm (2000) 1.39
Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leuk Res (2000) 1.39
Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology (1999) 1.35
Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother (2009) 1.31
Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood (1995) 1.30
Bitumen morphologies by phase-detection atomic force microscopy. J Microsc (2006) 1.29
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol (1993) 1.29
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia (2012) 1.23
Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet (1987) 1.22
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia (2007) 1.22
Stem cell transplantation in a patient with late-onset nemaline myopathy and gammopathy. Neurology (2008) 1.20
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J (2001) 1.20
Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region. Proc Natl Acad Sci U S A (1999) 1.19
Towards novel paradigms for cancer therapy. Oncogene (2010) 1.18
Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis (1997) 1.17
Candida catenulata fungemia in a cancer patient. J Clin Microbiol (1999) 1.17
Characterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development. Blood (1993) 1.15
Oligoclonal expansion of CD8+ CD57+ T cells with restricted T-cell receptor beta chain variability after bone marrow transplantation. Blood (1994) 1.15
Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. Tissue Antigens (1997) 1.14
PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia (2009) 1.14
A retrospective series of gut aspergillosis in haematology patients. Clin Microbiol Infect (2011) 1.13
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol (1998) 1.12
[MALT-type B-cell lymphoma masquerading as scleritis or posterior uveitis]. J Fr Ophtalmol (2005) 1.12
Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood (1998) 1.11
Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis (1999) 1.09
Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest (1998) 1.08
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol (2009) 1.07
Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia (2012) 1.07
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood (2001) 1.06
Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother (2013) 1.05
Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs. Am J Med (1991) 1.05
Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med (2001) 1.04
A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood (1991) 1.04
Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation (1994) 1.03
The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis (1995) 1.03
Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology (1997) 1.02
Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis (2014) 1.02
Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood (2000) 1.02
Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry (2007) 1.01
AIDS-related cholangiopathy. Critical analysis of a prospective series of 26 patients. Dig Dis Sci (1993) 1.01
Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte. Br J Cancer (1994) 1.01
LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol (1989) 1.01
CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol (1998) 1.00
An inhibitor of cytotoxic functions produced by CD8+CD57+ T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur J Immunol (1994) 1.00
Direct infection of CD34+ progenitor cells by human cytomegalovirus: evidence for inhibition of hematopoiesis and viral replication. Blood (1996) 0.99
Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect (2013) 0.99
Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J (2005) 0.98
Genomic anatomy of a premier major histocompatibility complex paralogous region on chromosome 1q21-q22. Genome Res (2001) 0.98
Compression wood-responsive proteins in developing xylem of maritime pine (Pinus pinaster ait.). Plant Physiol (2000) 0.98
Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia (1997) 0.98
Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells. J Exp Med (1988) 0.97
Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases. Leukemia (2006) 0.97
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia (2005) 0.97
Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol (2001) 0.97
Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect (2006) 0.97
High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood (1993) 0.96
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother (2009) 0.96
AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol (2005) 0.96
Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. Tissue Antigens (2004) 0.96
Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behçet's disease. Arthritis Rheum (1999) 0.96
Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest (1992) 0.96